NIH R01 · 2025
Chronic kidney disease (CKD) affects 40% of older adults (≥65 years), and is a significant contributor to morbidity, mortality, and healthcare spending. Although older adults with CKD are more likely to be diagnosed with multiple chronic conditions, take multi-drug regimens, and owing to pharmaco- dynamic and -kinetic modulations, are uniquely susceptible to experiencing drug-related harms, they are routinely excluded from clinical trials. Thus, there is an urgent need to examine the safety and effectiveness of medications in this population. In response to this unmet need, this proposal will study the effects of medications in older CKD adults. We will focus on cardiometabolic drugs as…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.